大剂量胸腺肽联合阿昔洛韦治疗复发性口疮的临床研究

Clinical observation of recurrent oral ulcers treated by high-dose thymosin combined with acyclovir

目的 观察大剂量胸腺肽联合阿昔洛韦治疗复发性口疮的治疗疗效 ,探讨胸腺肽治疗复发性口疮的机制。方法 收集复发性口疮 (ROU)患者 3 8例 ,随机分为治疗组 2 5例 ,对照组 13例。治疗组为大剂量胸腺肽联合阿昔洛韦治疗 ,对照组为单纯用阿昔洛韦治疗。患者治疗前及治疗后 3个月抽取静脉血 2ml,用免疫酶法检测T细胞亚群数值。结果 治疗组和对照组 3个月内复发率无明显差异 ,而 6个月、1年、2年的复发率分别为 16%、3 2 %、60 %和 3 0 .76%、69.2 2 %、10 0 %。治疗组治疗后 3个月的CD3、CD4、CD4 CD8比值明显升高 (P <0 .0 1) ,CD8无明显变化 (P >0 .0 5 )。对照组治疗后 3个月的CD3、CD4、CD8、CD4 CD8比值没明显改变。结论 胸腺肽可通过调节细胞免疫功能 ,阻止或减轻ROU的复发 ,大剂量胸腺肽联合阿昔洛韦治疗复发性口疮是安全。

Objective To observe the therapeutic effect on recurrent oral ulcers (ROU) by high dose thymosin combined with acyclovir,and to investigate the action mechanism.Methods 38 ROU patients were randomly divided into treatment group (n=25) and control group (n=13).The patients in treatment group were treated by a high dose thymosin combined with acyclovir;control group was treated by acyclovir only.Venous blood 2 ml was drawn from the patients three months before and after the treatment.The T cell subgroups was tested by immunoenzyme assay.Results There was no significant difference in recurrence rate between treatment group and control group within three months after the therapy,however,six months,one year and two years after the treatment the recurrence rate was 16%,32%,60% in treatment group and 30.76%,69.22%,100% in control group respectively.Three months after the treatment,in treatment group CD3,CD4,CD4/CD8 ratio improved significantly (P<0.01),while CD8 was not changed obviously;in control group there were no remarkable changes in CD3,CD4,CD8,CD4/CD8 ratio.Conclusion Thymosin can prevent or suppress the recurrence of ROU by adjusting cellular immunologic function,treating ROU with high dose thymosin combined with acyclovir is a safe and effective method.